Is NNBXF or QYLD a better dividend investment in 2026?

NNBXF currently yields 21.98% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: NNBXF offers higher current income.

What is the dividend yield difference between NNBXF and QYLD?

NNBXF has a forward dividend yield of 21.98% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 10.06 percentage points.

Home › Compare › NNBXF vs QYLD

NNBXF vs QYLD: Dividend Comparison 2026

NNBXF yields 21.98% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 NNBXF wins by $57.0K in total portfolio value

INVESTMENT

TIME HORIZON10 years

NNBXF

● Live price

21.98%

Share price

$9.10

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$82.4K

Annual income

$8,278.86

Full NNBXF calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — NNBXF vs QYLD

📍 NNBXF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	NNBXF	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, NNBXF + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

NNBXF pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NNBXF

Annual income on $10K today (after 15% tax)

$1,868.13/yr

After 10yr DRIP, annual income (after tax)

$7,037.03/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, NNBXF beats the other by $2,226.62/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NNBXF + QYLD for your $10,000?

NNBXF: 50%QYLD: 50%

100% QYLD50/50100% NNBXF

Portfolio after 10yr

$53.9K

Annual income

$6,969.09/yr

Blended yield

12.93%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NNBXF buys

QYLD buys

No recent congressional trades found for NNBXF or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricNNBXFQYLD

Forward yield	21.98% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$82.4K ✓	$25.4K
Annual income after 10y	$8,278.86 ✓	$5,659.31
Total dividends collected	$49.1K ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: NNBXF vs QYLD ($10,000, DRIP)

Year	NNBXF Portfolio	NNBXF Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$12,898	$2,197.80	$10,352	$1,192.36	+$2.5K → NNBXF
2	$16,450	$2,649.24	$10,830	$1,347.57	+$5.6K → NNBXF
3	$20,759	$3,157.79	$11,460	$1,539.07	+$9.3K → NNBXF
4	$25,937	$3,724.32	$12,275	$1,777.84	+$13.7K → NNBXF
5	$32,101	$4,348.78	$13,323	$2,078.95	+$18.8K → NNBXF
6	$39,378	$5,030.23	$14,667	$2,463.34	+$24.7K → NNBXF
7	$47,902	$5,766.90	$16,396	$2,960.57	+$31.5K → NNBXF
8	$57,811	$6,556.21	$18,631	$3,612.97	+$39.2K → NNBXF
9	$69,253	$7,394.84	$21,548	$4,482.15	+$47.7K → NNBXF
10	$82,379	$8,278.86	$25,398	$5,659.31	+$57.0K → NNBXF

NNBXF vs QYLD: Complete Analysis 2026

NNBXF — Stock

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Full NNBXF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this NNBXF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NNBXF vs SCHD NNBXF vs JEPI NNBXF vs O NNBXF vs KO NNBXF vs MAIN NNBXF vs XYLD NNBXF vs JEPQ NNBXF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.